August 3, 2022 10:25 AM EDT
R&D

De­spite $5B sales for Keytru­da, Mer­ck hits two PhI­II snags as it con­tin­ues to build its multi­bil­lion-dol­lar drug

Lei Lei Wu

News Reporter

Con­tin­u­ing on its quest to grow Keytru­da’s block­buster sta­tus ahead of a 2028 patent cliff, Mer­ck re­port­ed to­day that Keytru­da has missed in two in­di­ca­tions …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times